What are healthy approaches to dieting?

Take our Healthy Lifestyle Test

Find a health professional

GLP-1 was built for obesity, but now the eligibility bar has almost disappeared.

Sixty-one percent of U.S. women want to lose weight, unchanged since 1951, a desire that is largely cultural.

The GLP-1 ads quote a monthly price, but the psychological one is still unknown.

Two hours. That is how long it takes, in 2026, to go from opening a website to receiving a GLP-1 prescription in your inbox. A questionnaire (asking for your height and weight, no fact-checking), a remote review by a clinician you will never meet, and a confirmation arrives.

A prescription used to mean a doctor had looked at you, assessed a condition, and determined that medical intervention was necessary.

But the woman completing the short questionnaire on her phone is not sick. She just wants to fit back into the jeans she hasn't worn in two years. She did her research, she can afford the medication, and she has spent years managing her body the hard way, counting, restricting, working out, with far less to show for it. So when the confirmation arrives in her inbox, she doesn't feel like a patient. She feels like a woman who finally has access to something that actually works.

Do we leave it there, or do we ask what it means that access to a powerful prescription medication now requires nothing more than a credit card and a wifi connection?

When semaglutide was first approved for weight management, you needed a body mass index (BMI) of 30 or higher, or a documented medical condition. The drug was designed for people whose weight was defined as a chronic disease. Then the thresholds disappeared. In March 2024, the Food and Drug Administration removed the specific........

© Psychology Today